

Original Article  
Respiratory Diseases



# Association between Genetic Variations of *MERTK* and Chronic Obstructive Pulmonary Disease in Koreans

Woo Jin Kim <sup>1,\*</sup> Hyo Jin Park <sup>2,\*</sup> Yang Ji Choi <sup>2</sup> Eun Young Kwon <sup>2</sup>  
Bo Min Kim <sup>2</sup> Jin Hwa Lee <sup>3</sup> Jung Hyun Chang <sup>3</sup> Jihee Lee Kang <sup>4</sup>  
and Ji Ha Choi <sup>2</sup>

OPEN ACCESS

**Received:** Sep 19, 2017

**Accepted:** Dec 12, 2017

**Address for Correspondence:**

Ji Ha Choi, MD, PhD

Department of Pharmacology, Tissue Injury  
Defense Research Center, College of Medicine,  
Ewha Womans University, 1071 Anyangcheon-ro,  
Yangcheon-gu, Seoul 07985, Korea.  
E-mail: jihachoi@ewha.ac.kr

\*Woo Jin Kim and Hyo Jin Park contributed  
equally to this work.

© 2018 The Korean Academy of Medical  
Sciences.

This is an Open Access article distributed  
under the terms of the Creative Commons  
Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>)  
which permits unrestricted non-commercial  
use, distribution, and reproduction in any  
medium, provided the original work is properly  
cited.

**ORCID iDs**

Woo Jin Kim   
<https://orcid.org/0000-0003-2927-370X>  
Hyo Jin Park   
<https://orcid.org/0000-0002-9709-7122>  
Yang Ji Choi   
<https://orcid.org/0000-0003-2213-247X>  
Eun Young Kwon   
<https://orcid.org/0000-0001-8743-7915>  
Bo Min Kim   
<https://orcid.org/0000-0003-0272-6676>  
Jin Hwa Lee   
<https://orcid.org/0000-0003-0843-9862>  
Jung Hyun Chang   
<https://orcid.org/0000-0003-1000-2491>  
Jihee Lee Kang   
<https://orcid.org/0000-0003-0998-3712>

<sup>1</sup>Department of Internal Medicine and Environmental Health Center, Kangwon National University, Chuncheon, Korea

<sup>2</sup>Department of Pharmacology, Tissue Injury Defense Research Center, College of Medicine, Ewha Womans University, Seoul, Korea

<sup>3</sup>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea

<sup>4</sup>Department of Physiology, Tissue Injury Defense Research Center, College of Medicine, Ewha Womans University, Seoul, Korea

## ABSTRACT

**Background:** Chronic obstructive pulmonary disease (COPD) is a debilitating lung disease. To date, a large number of clinical studies have been conducted to investigate the association between genetic variations and COPD. However, little is known regarding the genetic susceptibility of Koreans to this disease. MER receptor tyrosine kinase (*MERTK*) plays important roles in the inhibition of inflammation and in the clearance of apoptotic cells. Here, we investigated the association between genetic variations in *MERTK* and the development of COPD in Koreans.

**Methods:** We conducted genetic analysis of *MERTK* using genomic DNA samples from 87 patients with COPD and 88 healthy controls and compared the frequency of each variation or haplotype between the patient and control groups. Subsequently, the effect of each variation was evaluated using in vitro assays.

**Results:** Ten variations were identified in this study, four of them for the first time. In addition, we found that the frequency of each variation or haplotype was comparable between the patient and control groups. However, we observed that the frequency for the wild-type haplotype was higher in the control group, compared to that in the group of patients with COPD, in the subgroup analysis of current smokers, although the difference was not statistically significant ( $P = 0.080$ ). In in vitro assays, we observed that none of the variations affected the activity of the promoter or the expression of *MERTK*.

**Conclusion:** Our findings indicate that the susceptibility to COPD is not related to the genetic variations or haplotypes of *MERTK* in Koreans.

**Keywords:** *MERTK*; COPD; Haplotype; Association; Functional Characterization; Smoking

Ji Ha Choi <https://orcid.org/0000-0003-3678-1032>**Funding**

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIT) (2010-0027945) and Korea Biobank Projects (4851-307, KBP-2012-009) that were supported by the Korea Center for Disease Control and Prevention, Korea.

**Disclosure**

The authors have no potential conflicts of interest to disclose.

**Author Contributions**

Conceptualization: Kim WJ, Lee JH, Chang JH, Kang JL, Choi JH. Data acquisition: Kim WJ, Park HJ, Choi YJ, Kwon EY, Kim BM, Lee JH, Chang JH. Data analysis: Kim WJ, Park HJ, Choi YJ, Kwon EY, Kim BM, Lee JH, Choi JH. Writing - original draft: Kim WJ, Park HJ, Choi YJ, Kang JL, Choi JH.

**INTRODUCTION**

Chronic obstructive pulmonary disease (COPD) is a chronic lung disorder characterized by largely not full reversible and progressive airway obstructions.<sup>1,2</sup> COPD is the fourth leading cause of mortality, and will become the third by 2020.<sup>1,3</sup> Though it is well known that smoking represents a major risk factor for COPD, genetic factors could also affect the development of this disease.<sup>1,2</sup> To date, a large number of studies have investigated the association between genetic variations and COPD. For example, a study by Soler Artigas et al.<sup>4</sup> reported that single nucleotide polymorphisms (SNPs) in tensin 1, the C-terminal domain of glutathione S-transferase, and in 5-hydroxytryptamine receptor 4 were associated with susceptibility to COPD. Another study by Zhou et al.<sup>5</sup> found that several functional SNPs upstream of the hedgehog interacting protein were associated with severe COPD. Recently, several genome-wide association studies were conducted to investigate the susceptibility to COPD.<sup>6-9</sup> Based on the results of multiple meta-analyses, several SNPs that affect the Clara cell secretory protein or surfactant protein D, SNPs in cholinergic nicotinic receptor genes (CHRNA5/3), in serpin family A member 1, and in rs7937 on chromosome 19q13, show a significant association with susceptibility to COPD. However, few studies have investigated the role of genetic effects on the susceptibility to COPD in Koreans. Previous studies have reported that SNPs in interleukin-1B (IL-1B), IL-1 receptor antagonist (IL-1RA), serine peptidase inhibitor clade E2, matrix metalloproteinase-9, and CHRNA3 were associated with susceptibility to COPD in Korean populations.<sup>6,10-12</sup>

MER receptor tyrosine kinase (MERTK) is a member of the Axl/Mer/Tyro3 receptor tyrosine kinase family that can be activated by an endogenous ligand known as the growth-arrest-specific gene 6 (Gas6) or by protein S.<sup>13,14</sup> It is known that MERTK plays an important role in the inhibition of inflammation and in the clearance of apoptotic cells.<sup>14,15</sup> Previous studies have reported that mutations in *MERTK* are associated with several human diseases, such as retinal dystrophy and multiple sclerosis.<sup>16-19</sup> Recently, it was reported that the inhibition of MERTK enhanced inflammatory responses in lipopolysaccharide-induced acute lung injuries.<sup>20,21</sup> In addition, Kazeros et al.<sup>22</sup> found that the expression of MERTK was significantly increased in healthy cigarette smokers, compared to its expression in healthy non-smokers, and they suggested that this upregulation of MERTK might reflect the increased demand for the removal of apoptotic cells in smokers.

Here, we investigated whether genetic variations in *MERTK* affect the development of COPD in Koreans. We screened genomic DNA samples from 87 patients with COPD and 88 healthy controls, to identify variations in *MERTK*. Then, we examined the effect of each variation on the promoter activity or the expression of MERTK using in vitro assays.

**METHODS****Subjects**

For the case group, 87 genomic DNA samples were collected from patients with COPD who had been diagnosed by specialists in respiratory medicine at the Ewha Womans University Medical Center, or at the Kangwon National University Hospital, according to the guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD)<sup>23</sup>; the inclusion criteria for COPD in the present study were a post-bronchodilator ratio of forced expiratory volume in 1 second (FEV<sub>1</sub>) to forced vital capacity (FVC) of < 0.7. For the control group, 88 genomic DNA

samples were collected from healthy individuals from the DNA bank of the Korea Centers for Disease Control and Prevention, Korea, or from the Kangwon National University Hospital. Demographic information such as age, sex, smoking history, and height of subjects in the control group was obtained from the Korean Genome and Epidemiology Study (4851-302) of the Korea Centers for Disease Control and Prevention, or from the Kangwon National University Hospital. Other inclusion criteria for the control group were normal findings from chest X-rays, and no history of asthma, chronic pulmonary disease, or tuberculosis.

### Genetic analysis of *MERTK*

At first, we performed sequencing or genotyping using genomic DNA from 87 patients with COPD. To identify genetic variations in the promoter region of *MERTK*, a region including 2 kb upstream of the translational start site was sequenced using an automated genetic analyzer (Life Technologies Corporation, Carlsbad, CA, USA), or genotyped using the SNaPshot assay (Life Technologies Corporation). In addition, to identify genetic variations in the coding region of *MERTK*, the entire *MERTK* coding region was analyzed. Then, genotype screening for the identification of genetic variations in the promoter or coding regions in the 88 control subjects was performed using the SNaPshot assay. Haplotype assembly was performed using the Haploview software (version 4.3; Broad Institute, Cambridge, MA, USA). Nucleotide location numbers were assigned from the translational start site, based on the *MERTK* mRNA sequence (GenBank accession number; NM\_006343.2).

### Construction of plasmids containing wild-type *MERTK* and its variants

To construct a reporter plasmid containing the *MERTK* promoter region, this 1,625-bp region in *MERTK* was amplified from genomic DNA samples, using the NM\_006343.2 reference sequence and primers that contained recognition sites for the HindIII and XhoI restriction endonucleases. The amplified products were inserted into the pGL4.11b[*luc2*] vector (Promega Corporation, Fitchburg, WI, USA). To construct a plasmid containing the wild-type *MERTK* gene, a vector (Addgene plasmid 23900) was purchased (Addgene, Cambridge, MA, USA)<sup>24</sup> and subcloned into the pcDNA3.1 (+) vector (Life Technologies Corporation). Genetic variations in the promoter and in the coding region were obtained using the QuikChange® II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). All DNA sequences were confirmed by direct sequencing. The primers used in this study are listed in Supplementary Table 1.

### Measurement of *MERTK* promoter activity

Reporter plasmids containing the wild-type copy of *MERTK* or its variants were transfected into HCT-116 (human colon carcinoma) cells using Lipofectamine LTX and Plus reagents (Life Technologies Corporation). Thirty hours after transfection, the activity of the reporters was measured using the Dual-Luciferase® reporter assay system (Promega Corporation) according to the manufacturer's protocol, and quantified using a luminometer (Promega Corporation). The amount of transfected plasmid was normalized by using the pGL4.74 renilla vector. The firefly to renilla luciferase ratios were determined, and defined as the relative luciferase activity.

### Immunoblotting

The *MERTK* wild-type or variation-bearing plasmids were transfected into HCT-116 cells using the Lipofectamine LTX and Plus reagents. Forty-eight hours after transfection, cells were harvested and lysed in the NP-40 cell lysis buffer, supplemented with a protease inhibitor cocktail. After centrifugation for 20 minutes at  $14,000 \times g$  at 4°C, protein concentrations were determined using the BCA assay (Thermo Fisher Scientific

Inc., Waltham, MA, USA), and 50 µg of protein were loaded onto an SDS-PAGE gel. To characterize the glycosylated isoform of MERTK, 3 µL of endoH (New England Biolabs Ltd., Ontario, Canada) or 2 µL of PNGaseF (New England Biolabs Ltd.) were incubated with 10 µg of protein, and enzymatic digestion was conducted according to the manufacturer's protocol. Then, the proteins were separated on a 4%–12% SDS-PAGE gel, and transferred onto nitrocellulose membranes. The membranes were blocked for 1 hour with 5% (wt/vol) skimmed milk in Tris-buffered saline (140 mmol/L NaCl, 20 mmol/L Tris HCl, pH 7.6) and 0.1% (wt/vol) Tween-20. After blocking, the membranes were incubated with the following primary antibodies: a mouse anti-MERTK antibody (sc-365499; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or a goat anti-β-actin antibody (sc-1616; Santa Cruz Biotechnology). This was followed by an incubation with the corresponding secondary antibodies in blocking buffer, and the blots were developed using the ECL detection system (GH Healthcare Life Sciences, Pittsburgh, PA, USA). The intensity of each band was measured using ImageJ (National Institutes of Health, Bethesda, MD, USA).

### Statistical analysis

Data analysis was conducted using the IBM SPSS Statistics software (version 23; IBM Corporation, Armonk, NY, USA). *P* values for the luciferase assay and immunoblotting were calculated using a one-way analysis of variance, followed by Dunnett's two-tailed test and Student's two-tailed *t*-test, respectively. In addition, the  $\chi^2$ -test was used to compare the frequency of genetic variations, or to compare the haplotypes between the case and control groups. Finally, the comparisons of demographic or clinical characteristics between the case and control groups were performed using the  $\chi^2$ -test for categorical variables and Student's two-tailed *t*-test for continuous variables. *P* < 0.05 was considered significant.

### Ethics statement

This study was approved by the Institutional Review Board of the Ewha Womans University Mokdong Hospital (No. ECT 11-16-21) and by the Institutional Review Board of the Kangwon National University Hospital (No. KNUH 2012-06-007). All subjects provided written informed consent.

## RESULTS

### Genetic variations of MERTK in patients with COPD

Through direct sequencing or genotyping of genomic DNA from 87 patients with COPD, we identified three and seven variations in the promoter and coding regions of *MERTK*, respectively (Table 1). Two of the *MERTK* promoter variations, g.-538A>C and g.-41T>C, were first identified in this study. In the coding region, there were four nonsynonymous and three synonymous variations, and two of them, A489V and F512F, were novel.

### Comparison of the genetic variations in MERTK between the case and control groups

To compare the frequency of genetic variations in *MERTK* between patients with COPD and the control group, genotype screening of genetic variations in the promoter or coding regions was performed using genomic DNA from 88 healthy controls. The frequencies of the variations in *MERTK* in controls are listed in Supplementary Table 2. As a result, four rare variations that were found in the patient group, g.-41T>C, p.V469F, p.A489V, and p.F512F were absent in the control group. Table 2 shows the frequency of the ten variations between

**Table 1.** Frequency of *MERTK* genetic variations in patients with COPD

rs Number	Variations	Amino acid substitution	Minor allele frequency
Promoter variation			
rs6738898	g.-1351T>C		0.259
-	g.-538A>C		0.006
-	g.-41T>C		0.006
Coding variation			
rs3761702	c.756A>G	p.P252P	0.052
rs7604639	c.1397G>A	p.R466K	0.190
rs79943145	c.1405G>T	p.V469F	0.006
-	c.1466C>T	p.A489V	0.006
-	c.1536T>C	p.F512F	0.011
rs2230515	c.1552A>G	p.I518V	0.190
rs1131244	c.1881A>G	p.S627S	0.184

Data were obtained from DNA samples from 87 unrelated Korean patients with COPD. *MERTK* = MER receptor tyrosine kinase, COPD = chronic obstructive pulmonary disease.

**Table 2.** Frequency of *MERTK* genetic variations in case and control groups

Variations	Case, No.	Control, No.	P value
g.-1351T>C			0.600
+/+	51	55	
+/-	27	27	
-/-	9	6	
g.-538A>C			0.621
+/+	86	85	
+/-	1	3	
-/-	0	0	
g.-41T>C			0.497
+/+	86	88	
+/-	1	0	
-/-	0	0	
P252P			0.583
+/+	78	81	
+/-	9	7	
-/-	0	0	
R466K			0.487
+/+	56	61	
+/-	29	22	
-/-	2	5	
V469F			0.497
+/+	86	88	
+/-	1	0	
-/-	0	0	
A489V			0.497
+/+	86	88	
+/-	1	0	
-/-	0	0	
F512F			0.246
+/+	85	88	
+/-	2	0	
-/-	0	0	
I518V			0.487
+/+	56	61	
+/-	29	22	
-/-	2	5	
S627S			0.592
+/+	57	61	
+/-	28	22	
-/-	2	5	

Data were obtained from DNA samples from 87 unrelated Korean patients with COPD and 88 controls. *P* values (+/+ vs. +/- or -/-) were obtained by comparison with control using the  $\chi^2$  analysis. *MERTK* = MER receptor tyrosine kinase, + = major allele, - = minor allele, COPD = chronic obstructive pulmonary disease.

**Table 3.** Frequency of *MERTK* major haplotypes in case and control groups

ID	g.-1351T>C	g.-538A>C	g.-41T>C	P252P	R466K	V469F	A489V	F512F	I518V	S627S	Frequency, %	Case, No. (%)	Control, No. (%)	P value
H1	T	A	T	A	G	G	C	T	A	A	55.1	91 (52.3)	102 (58.0)	0.287
H2	<u>C</u>	A	T	A	G	G	C	T	A	A	22.8	44 (25.3)	36 (20.5)	0.282
H3	T	A	T	A	<u>A</u>	G	C	T	<u>G</u>	<u>G</u>	14.7	23 (13.2)	28 (15.9)	0.476

The minor alleles were marked in bold-faced letters with underlines.

*MERTK* = MER receptor tyrosine kinase.

**Table 4.** Demographic and clinical characteristics of subjects in case and control groups

Parameters	Case (n = 87)	Control (n = 88)	P value
Age, yr	72.75 ± 6.72	67.82 ± 6.29	< 0.010
Sex (male), No.	69	73	0.567
Height, cm	159.63 ± 9.80	161.75 ± 7.68	0.114
Smoking, pack/yr	26.94 ± 22.33	26.95 ± 23.47	0.997
FEV <sub>1</sub>	1.57 ± 0.53	2.51 ± 0.63	< 0.010
FEV <sub>1</sub> /FVC, %	57.26 ± 10.49	74.46 ± 4.65	< 0.010

All values are expressed as mean ± standard deviation or number (%).

FEV<sub>1</sub> = forced expiratory volume in 1 second, FVC = forced viral capacity.

the two groups. We observed that there was no significant difference in the frequency of genetic variations in *MERTK* between the two groups. Using genotype data, haplotypes were assembled. There were three major (frequency ≥ 5%) haplotypes in our study population (Table 3). We observed that the frequency of major haplotypes in patients with COPD was comparable to that of the control group. In addition, there was no significant difference in sex, height, and smoking history between the control and case groups (Table 4). In the case of pulmonary function, the FEV<sub>1</sub> and FEV<sub>1</sub>/FVC were much lower in the case group, when compared to those in the control group ( $P < 0.01$ ).

### Comparison of the genetic variations in *MERTK* in current smokers

Because smoking represents a major risk factor for COPD, we compared the frequency of *MERTK* variations in current smokers only; within the COPD patient group, there were 46 smokers, while in the control group there were 56 smokers. Tables 5 and 6 show the frequencies of the variations, or those of the major haplotypes in *MERTK* in the two groups, respectively. The frequency of each variation in the patient group was comparable with that in the control group. However, we observed that the frequency of the wild-type haplotype (H1) was higher in the control group, although the difference was not statistically significant ( $P = 0.080$ ). The smoking history was not significantly different between the two groups (Table 7). To confirm our findings for the subgroup analysis, a future analysis including a larger number of samples will be necessary.

### Effects of the variations on the promoter activity of *MERTK*

To our knowledge, no study has investigated the function of each *MERTK* variation. Therefore, to characterize the functional effects of promoter variations, we constructed a reporter plasmid containing the *MERTK* reference sequence, and a luciferase assay was performed 30 hours after the transfection of the reporter plasmid into HCT-116 cells. As a result, the *MERTK* wild-type vector containing the 1,625-bp *MERTK* promoter region, displayed a 51-fold increase in promoter activity, compared to that in the empty vector (EV) (Fig. 1A). To examine the effect of *MERTK* variations on promoter activity, we constructed plasmids containing the variant sequences. After performing luciferase assays, we observed that the promoter activities of three variations, g.-1351T>C, g.-538A>C, and g.-41T>C were comparable with that of the wild-type (Fig. 1B).



**Table 5.** Frequency of *MERTK* genetic variations in current smokers

Variations	Case, No.	Control, No.	P value
g.-1351T>C			0.112
+/+	25	39	
+/-	17	14	
-/-	4	3	
g.-538A>C			1.000
+/+	45	55	
+/-	1	1	
-/-	0	0	
g.-41T>C			0.451
+/+	45	56	
+/-	1	0	
-/-	0	0	
P252P			0.538
+/+	40	51	
+/-	6	5	
-/-	0	0	
R466K			0.191
+/+	29	42	
+/-	17	10	
-/-	0	4	
V469F			0.451
+/+	45	56	
+/-	1	0	
-/-	0	0	
A489V			0.451
+/+	45	56	
+/-	1	0	
-/-	0	0	
F512F			0.201
+/+	44	56	
+/-	2	0	
-/-	0	0	
I518V			0.191
+/+	29	42	
+/-	17	10	
-/-	0	4	
S627S			0.281
+/+	30	42	
+/-	16	10	
-/-	0	4	

Data were obtained from DNA samples from 46 unrelated Korean patients with COPD and 56 healthy controls. All participants were smokers. *P* values (+/+ vs. +/- or -/-) were obtained by comparison with control using the  $\chi^2$  analysis. *MERTK* = MER receptor tyrosine kinase, + = major allele, - = minor allele, COPD = chronic obstructive pulmonary disease.

**Table 6.** Frequency of *MERTK* major haplotypes in current smokers

ID	g.-1351T>C	g.-538A>C	g.-41T>C	P252P	R466K	V469F	A489V	F512F	I518V	S627S	Frequency, %	Case, No. (%)	Control, No. (%)	P value
H1	T	A	T	A	G	G	C	T	A	A	58.6	48 (52.2)	72 (64.3)	0.080
H2	<u>C</u>	A	T	A	G	G	C	T	A	A	20.0	22 (23.9)	19 (17.0)	0.386
H3	T	A	T	A	<u>A</u>	G	C	T	<u>G</u>	<u>G</u>	12.1	9 (9.8)	15 (13.4)	0.218

The minor alleles were marked in bold-faced letters with underlines.


*MERTK* = MER receptor tyrosine kinase.

**Table 7.** Demographic and clinical characteristics of current smokers

Parameters	Case (n = 46)	Control (n = 56)	P value
Age, yr	71.54 ± 6.90	65.43 ± 4.17	< 0.010
Sex (male), No.	46	56	
Height, cm	163.41 ± 6.44	164.55 ± 4.51	0.214
Smoking, pack/yr	40.54 ± 18.23	35.43 ± 19.80	0.182
FEV <sub>1</sub>	1.66 ± 0.52	2.75 ± 0.54	< 0.010
FEV <sub>1</sub> /FVC, %	52.15 ± 9.21	74.84 ± 4.55	< 0.010

All values are expressed as mean ± standard deviation or number (%).


FEV<sub>1</sub> = forced expiratory volume in 1 second, FVC = forced viral capacity.



**Fig. 1.** Luciferase activity of wild-type *MERTK* and its variants. Luciferase activity measured 30 hours after the transfection of (A) the *MERTK* wild-type reporter plasmid or (B) reporter plasmids containing *MERTK* variants into HCT-116 cells. The luciferase activity of each construct is compared to that of the empty vector (EV, pGL4.11b[*luc2*]) (A) or the *MERTK* wild-type (B). The data (mean  $\pm$  standard deviation) represent triplicate measurements from a representative experiment. *MERTK* = MER receptor tyrosine kinase.

### Effects of the variations on the expression of MERTK

To investigate whether variations in the *MERTK* coding region could affect *MERTK* protein expression, we performed an immunoblotting assay, following the transfection of *MERTK* plasmids into HCT-116 cells. As shown in Fig. 2A, *MERTK* was detected as two distinct bands on the western blot. We further examined the glycosylation status of *MERTK* after treatment



**Fig. 2.** The effect of genetic variations on *MERTK* expression. (A) Immunoblotting assays performed using cell lysates obtained 48 hours after the transfection of wild-type *MERTK* plasmids into HCT-116 cells, in the presence of endoH (lane 2) or PNGaseF (lane 3), to examine the glycosylation status of *MERTK*. (B) Immunoblotting assays performed after transfection of wild-type *MERTK* or variant *MERTK* plasmids. The *MERTK* expression level for each variant is compared with that of the wild-type. The data (mean  $\pm$  standard deviation) is obtained from three representative experiments.  $\beta$ -actin is used as an internal control. *MERTK* = MER receptor tyrosine kinase.



with endoH or PNGaseF, followed by immunoblotting. We therefore found that the lower 140 kDa band shifted to a lower molecular weight after endoH treatment, while the upper 160 kDa band was not affected. After treatment with PNGaseF, the molecular weight of both bands had changed, suggesting that both isoforms had been deglycosylated. These data suggest that the upper band represents the fully mature, glycosylated form of MERTK, while the lower band represents the endoH-sensitive, high mannose form of MERTK. Therefore, we compared the densities of the upper bands between the wild-type *MERTK* and its variants, to determine the effect of variations in *MERTK* on its protein expression. As a result, among the seven nonsynonymous and synonymous variations, none displayed a significant difference in MERTK expression, when compared to that in the wild-type (Fig. 2B).

## DISCUSSION

MERTK is expressed ubiquitously on macrophages, and can be activated by Gas6 and protein S. Moreover, it negatively regulates inflammation and removes apoptotic cells after recognizing the 'eat-me' phosphatidylserine signal on these cells.<sup>25</sup> The dysregulation of the immune response, or the inappropriate removal of apoptotic cells or of the debris, caused by a dysfunction in MERTK, can result in various diseases such as autoimmune diseases, chronic inflammatory diseases, and cancers.<sup>26</sup> For example, genome-wide studies have reported the association between *MERTK* variations and the susceptibility to multiple sclerosis.<sup>19,27</sup> In addition, it is known that protein S, one of the ligands of MERTK presents an anti-inflammatory function, and is reduced in patients with ulcerative colitis or Crohn's disease.<sup>28,29</sup> In a mouse model, it was reported that a lupus-like disease was induced in *MerTK*-null mice, while another study reported that the overexpression of *MerTK* in mice could result in lymphoblastic leukemia/lymphoma.<sup>30,31</sup>

In the airways, the clearance of apoptotic cells by MERTK is critical for the maintenance of lung homeostasis. Several studies have reported that the clearance of apoptotic immune or bronchial epithelial cells was decreased in patients with COPD, when compared to that in healthy controls.<sup>32,33</sup> In particular, this phenomenon was notably observed in smokers with COPD.<sup>33</sup> The clearance of apoptotic cells by airway macrophages could be impaired by several factors, such as oxidative stress, that could be triggered by cigarette smoking and high mobility group protein-1.<sup>34-36</sup> Interestingly, it was observed that the expression of MERTK on airway macrophages was significantly increased in healthy cigarette smokers, compared to that in healthy non-smokers, and it was proposed that this upregulation in MERTK might reflect the increased demand for the removal of apoptotic cells in smokers in this study.<sup>22</sup>

In the present study, we hypothesized that the dysfunction in MERTK caused by genetic variations might be associated with the development of COPD. To investigate this, we screened genomic DNA samples from 87 Korean patients with COPD and from 88 healthy controls, and found that the frequencies of the variations or the haplotypes of *MERTK* were comparable between the two groups. Interestingly, four variations, including one promoter variation, two nonsynonymous variations, and one synonymous variation were found only in the patient group, even though the frequency of all variations was much lower in that group. In particular, three of these variations were first identified in this study. To evaluate whether these variations are COPD-specific or not, a future genetic analysis, including a larger number of samples, will be necessary. It is well accepted that cigarette smoking represents

the most important risk factor for COPD; smoking induces inflammatory reactions in the airways, and suppresses the innate and adaptive immunity in the lung.<sup>37</sup> Therefore, we compared the frequency of *MERTK* variations in smokers, and observed that the frequency of the wild-type haplotype was higher in the control group, although the difference was not statistically significant ( $P = 0.080$ ).

To the best of our knowledge, no study has reported the effect of variations in *MERTK* on its gene expression. Therefore, we evaluated the effect of the *MERTK* variations found in our study population on *MERTK* promoter activity or expression, using in vitro assays. As a result, none of the variations, including three promoter variations, four nonsynonymous variations, and three synonymous variations, showed an effect on the promoter activity or the expression of *MERTK*.

There are several limitations in the present study. First, the number of samples was small and therefore insufficient for the results to be statistically significant. In particular, the number of smokers was extremely small. Recently, Hancock et al.<sup>38</sup> performed a genome-wide joint meta-analysis to examine the association between genetic variations and lung function, following the investigation of SNP-by-smoking interactions. In another study, stratified genetic association analyses were conducted, according to smoking intensity, to evaluate the association between SNPs and the susceptibility to COPD.<sup>39</sup> However, because of the small number of samples, these analyses were not performed in this study. Second, all participants in this study were of East-Asian descent. Therefore, the types and frequencies of the genetic variations could be ethnic-specific. Finally, we could not measure whether the ability of *MERTK* to remove apoptotic cells is affected in its variants. It is well known that the function of proteins such as enzymes, transporters, and receptors can be impaired, even when their expression remains unaffected. For example, Gautherot et al.<sup>40</sup> reported that two nonsynonymous mutations in the multidrug resistance 3 (*MDR3*) transporter, encoded by the ATP-binding cassette, subfamily B, member 4 gene (*ABCB4*) led to a significant decrease in its transport ability, although none of these variations affected the expression of *MDR3*. It was subsequently found that the phosphorylation of *ABCB4* was impaired by these mutations. Therefore, to clarify the effect of the *MERTK* variants found in our study, further functional evaluation will be required.

In conclusion, we identified ten variations in *MERTK* in Koreans. The frequency of each variation was comparable between patients with COPD and healthy control groups. However, in the subgroup analysis that included smokers, the frequency of the wild-type haplotype was higher in the control group, although the difference was not statistically significant. In addition, none of these variations had an effect on *MERTK* promoter activity or on its expression. To our knowledge, this is the first study to evaluate the association between genetic variations in *MERTK* and the susceptibility to COPD, along with the effect of each variation on *MERTK* expression by using in vitro assays. Because of the small sample size used in the present study, a further study with a larger number of samples including various ethnicities is necessary to investigate the utility of *MERTK* variations as predictors of COPD.

## ACKNOWLEDGMENTS

We thank W. Hahn and D. Root for deposit *MERTK* plasmid to Addgene.

## SUPPLEMENTARY MATERIALS

### Supplementary Table 1

Primers used in the construction of *MERTK* plasmids

[Click here to view](#)

### Supplementary Table 2

Frequency of *MERTK* genetic variations in healthy Koreans

[Click here to view](#)

## REFERENCES

- Di Marco F, Tantucci C, Pellegrino G, Centanni S. Chronic obstructive pulmonary disease diagnosis: the simpler the better? Not always. *Eur J Intern Med* 2013;24(3):199-202.  
[PUBMED](#) | [CROSSREF](#)
- Bauer CM, Morissette MC, Stämpfli MR. The influence of cigarette smoking on viral infections: translating bench science to impact COPD pathogenesis and acute exacerbations of COPD clinically. *Chest* 2013;143(1):196-206.  
[PUBMED](#) | [CROSSREF](#)
- Holloway RA, Donnelly LE. Immunopathogenesis of chronic obstructive pulmonary disease. *Curr Opin Pulm Med* 2013;19(2):95-102.  
[PUBMED](#) | [CROSSREF](#)
- Soler Artigas M, Wain LV, Repapi E, Obeidat M, Sayers I, Burton PR, et al. Effect of five genetic variants associated with lung function on the risk of chronic obstructive lung disease, and their joint effects on lung function. *Am J Respir Crit Care Med* 2011;184(7):786-95.  
[PUBMED](#) | [CROSSREF](#)
- Zhou X, Baron RM, Hardin M, Cho MH, Zielinski J, Hawrylkiewicz I, et al. Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. *Hum Mol Genet* 2012;21(6):1325-35.  
[PUBMED](#) | [CROSSREF](#)
- Kim DK, Cho MH, Hersh CP, Lomas DA, Miller BE, Kong X, et al. Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012;186(12):1238-47.  
[PUBMED](#) | [CROSSREF](#)
- Wilk JB, Shrine NR, Loehr LR, Zhao JH, Manichaikul A, Lopez LM, et al. Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. *Am J Respir Crit Care Med* 2012;186(7):622-32.  
[PUBMED](#) | [CROSSREF](#)
- Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL, et al. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. *Hum Mol Genet* 2012;21(4):947-57.  
[PUBMED](#) | [CROSSREF](#)
- Busch R, Hobbs BD, Zhou J, Castaldi PJ, McGeachie MJ, Hardin ME, et al. Genetic association and risk scores in a chronic obstructive pulmonary disease meta-analysis of 16,707 subjects. *Am J Respir Cell Mol Biol* 2017;57(1):35-46.  
[PUBMED](#) | [CROSSREF](#)
- Lee JM, Kang YR, Park SH, Cha SI, Kim JS, Kang HK, et al. Polymorphisms in interleukin-1B and its receptor antagonist genes and the risk of chronic obstructive pulmonary disease in a Korean population: a case-control study. *Respir Med* 2008;102(9):1311-20.  
[PUBMED](#) | [CROSSREF](#)
- Cha SI, Kang HG, Choi JE, Kim MJ, Park J, Lee WK, et al. SERPINE2 polymorphisms and chronic obstructive pulmonary disease. *J Korean Med Sci* 2009;24(6):1119-25.  
[PUBMED](#) | [CROSSREF](#)
- Lee SY, Kim MJ, Kang HG, Yoo SS, Choi YY, Lee WK, et al. Polymorphisms in matrix metalloproteinase-1, -9 and -12 genes and the risk of chronic obstructive pulmonary disease in a Korean population. *Respiration* 2010;80(2):133-8.  
[PUBMED](#) | [CROSSREF](#)

13. Chen J, Carey K, Godowski PJ. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. *Oncogene* 1997;14(17):2033-9.  
[PUBMED](#) | [CROSSREF](#)
14. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. *Nature* 2001;411(6834):207-11.  
[PUBMED](#) | [CROSSREF](#)
15. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. *Cell* 2007;131(6):1124-36.  
[PUBMED](#) | [CROSSREF](#)
16. Gal A, Li Y, Thompson DA, Weir J, Orth U, Jacobson SG, et al. Mutations in *MERTK*, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. *Nat Genet* 2000;26(3):270-1.  
[PUBMED](#) | [CROSSREF](#)
17. Thompson DA, McHenry CL, Li Y, Richards JE, Othman MI, Schwinger E, et al. Retinal dystrophy due to paternal isodisomy for chromosome 1 or chromosome 2, with homoallelism for mutations in RPE65 or *MERTK*, respectively. *Am J Hum Genet* 2002;70(1):224-9.  
[PUBMED](#) | [CROSSREF](#)
18. Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Wings A, et al. *MERTK* receptor tyrosine kinase is a therapeutic target in melanoma. *J Clin Invest* 2013;123(5):2257-67.  
[PUBMED](#) | [CROSSREF](#)
19. International Multiple Sclerosis Genetics Consortium Wellcome Trust Case Control Consortium 2 Sawcer S, Hellenthal G, Pirinen M, Spencer CC, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature* 2011;476(7359):214-9.  
[PUBMED](#) | [CROSSREF](#)
20. Lee YJ, Han JY, Byun J, Park HJ, Park EM, Chong YH, et al. Inhibiting Mer receptor tyrosine kinase suppresses STAT1, SOCS1/3, and NF- $\kappa$ B activation and enhances inflammatory responses in lipopolysaccharide-induced acute lung injury. *J Leukoc Biol* 2012;91(6):921-32.  
[PUBMED](#) | [CROSSREF](#)
21. Choi JY, Park HJ, Lee YJ, Byun J, Youn YS, Choi JH, et al. Upregulation of Mer receptor tyrosine kinase signaling attenuated lipopolysaccharide-induced lung inflammation. *J Pharmacol Exp Ther* 2013;344(2):447-58.  
[PUBMED](#) | [CROSSREF](#)
22. Kazeros A, Harvey BG, Carolan BJ, Vanni H, Krause A, Crystal RG. Overexpression of apoptotic cell removal receptor *MERTK* in alveolar macrophages of cigarette smokers. *Am J Respir Cell Mol Biol* 2008;39(6):747-57.  
[PUBMED](#) | [CROSSREF](#)
23. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SSGOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med* 2001;163(5):1256-76.  
[PUBMED](#) | [CROSSREF](#)
24. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. *Nature* 2010;468(7326):968-72.  
[PUBMED](#) | [CROSSREF](#)
25. Zagórska A, Través PG, Lew ED, Dransfield I, Lemke G. Diversification of TAM receptor tyrosine kinase function. *Nat Immunol* 2014;15(10):920-8.  
[PUBMED](#) | [CROSSREF](#)
26. Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S. TAM receptor signaling in immune homeostasis. *Annu Rev Immunol* 2015;33(1):355-91.  
[PUBMED](#) | [CROSSREF](#)
27. Ma GZ, Stankovich J, Kilpatrick TJ, Binder MD, Field JAustralia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Polymorphisms in the receptor tyrosine kinase *MERTK* gene are associated with multiple sclerosis susceptibility. *PLoS One* 2011;6(2):e16964.  
[PUBMED](#) | [CROSSREF](#)
28. Cakal B, Gokmen A, Yalinkilic M, Cakal E, Ayaz S, Nadir I, et al. Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease. *Blood Coagul Fibrinolysis* 2010;21(2):118-21.  
[PUBMED](#) | [CROSSREF](#)
29. Koutroubakis IE, Sfridaki A, Mouzas IA, Maladaki A, Kapsoritakis A, Roussomoustakaki M, et al. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. *Am J Gastroenterol* 2000;95(1):190-4.  
[PUBMED](#) | [CROSSREF](#)

30. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-met membrane tyrosine kinase. *J Exp Med* 2002;196(1):135-40.  
[PUBMED](#) | [CROSSREF](#)
31. Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (*MerTK*) receptor tyrosine kinase. *Oncogene* 2006;25(45):6092-100.  
[PUBMED](#) | [CROSSREF](#)
32. Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. *Immunol Cell Biol* 2003;81(4):289-96.  
[PUBMED](#) | [CROSSREF](#)
33. Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, Reynolds PN. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2007;37(6):748-55.  
[PUBMED](#) | [CROSSREF](#)
34. Hodge S, Matthews G, Mukaro V, Ahern J, Shivam A, Hodge G, et al. Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine. *Am J Respir Cell Mol Biol* 2011;44(5):673-81.  
[PUBMED](#) | [CROSSREF](#)
35. Liu G, Wang J, Park YJ, Tsuruta Y, Lorne EF, Zhao X, et al. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. *J Immunol* 2008;181(6):4240-6.  
[PUBMED](#) | [CROSSREF](#)
36. Grabiec AM, Hussell T. The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation. *Semin Immunopathol* 2016;38(4):409-23.  
[PUBMED](#) | [CROSSREF](#)
37. Nurwidya F, Damayanti T, Yunus F. The role of innate and adaptive immune cells in the immunopathogenesis of chronic obstructive pulmonary disease. *Tuberc Respir Dis* 2016;79(1):5-13.  
[PUBMED](#) | [CROSSREF](#)
38. Hancock DB, Soler Artigas M, Gharib SA, Henry A, Manichaikul A, Ramasamy A, et al. Genome-wide joint meta-analysis of SNP and SNP-by-smoking interaction identifies novel loci for pulmonary function. *PLoS Genet* 2012;8(12):e1003098.  
[PUBMED](#) | [CROSSREF](#)
39. Kim WJ, Lim MN, Hong Y, Silverman EK, Lee JH, Jung BH, et al. Association of lung function genes with chronic obstructive pulmonary disease. *Lung* 2014;192(4):473-80.  
[PUBMED](#) | [CROSSREF](#)
40. Gautherot J, Delautier D, Maubert MA, Aït-Slimane T, Bolbach G, Delaunay JL, et al. Phosphorylation of ABCB4 impacts its function: insights from disease-causing mutations. *Hepatology* 2014;60(2):610-21.  
[PUBMED](#) | [CROSSREF](#)